" class="no-js "lang="en-US"> Röchling Medical and Trendlines Innovation Labs Join Forces to Offer Top Innovation and Manufacturing Expertise to the Healthcare Industry - Medtech Alert
Friday, March 01, 2024

Röchling Medical and Trendlines Innovation Labs Join Forces to Offer Top Innovation and Manufacturing Expertise to the Healthcare Industry

Röchling Medical, a division of the German-based Röchling Group and a leading manufacturer for the healthcare industry, and Trendlines Innovation Labs, the innovation and R&D arm of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), announced a collaboration agreement to provide a one-stop-shop for medical device innovation, development, and manufacturing.

Röchling Medical is a renowned partner to leading pharmaceutical, biotech and medtech companies worldwide, offering complete manufacturing solutions and a wide range of high-quality, customized components and assemblies, including end-to-end OEM products. Röchling Medical brings a proven track record of serving the life science and pharmaceutical industry. As a manufacturing partner, Röchling Medical offers flexibility, responsiveness, and traceability – from start to finish.

Trendlines Innovation Labs is an innovation partner, inventing and investing with life science companies. Trendlines Innovation Labs brings a wealth of expertise in invention and R&D of breakthrough medical products with a focus on early-stage development. Trendlines Innovation Labs’ strength is its ability to invent new solutions and products with speed and focus, that meet critical unmet needs with an aim to improve the human condition.

The collaboration agreement leverages on the strengths of each party and on the grounds that by joining forces, the parties will expand and enhance the value proposition and offering of complete innovation, product development and manufacturing solutions to the healthcare industry, broadening their individual and joint endeavors.

Dr. Boris Fröhlich, President & CEO of Röchling Medical, commented: “We are enthusiastic about working together with Trendlines Innovation Labs. This collaboration addresses our partners’ needs to the fullest extent. We are amazed that we have entered into this great partnership to support our partners in providing health to the people around the globe.”

Nir Goldenberg, CEO of Trendlines Innovation Labs, added, “We are extremely excited about our collaboration with Röchling Medical. By joining forces we’ll be able to provide a greater value proposition for our partners, together with timely and quality delivery of product innovation, development, and manufacturing. By working together, we’ll significantly enhance our joint proposition, together with the product offering of our partners.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more